Viral vectors and viral vaccines based on recombinant porcine adenoviruses
US7109025B1 · kind B1 · utility
Assignees
Inventors
Key dates
| Filing date | Feb 8, 2000 |
| Grant date | Sep 19, 2006 |
| Priority date | — |
| Expiry date | Feb 8, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2710/16734
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
An in vivo replicative and recombined porcine adenovirus characterized in that it comprises a heterologous nucleotide sequence inserted into the porcine adenovirus in conditions enabling the latter to be replicated in vivo and to express the inserted heterologous nucleotide sequence, and in that the adenovirus genome comes from a 3 or 5 serotype (PAV-3 or PAV-5) adenovirus. Insertion occurs in a non-essential zone of the E3 region, preferably with deletion of said zone. The invention also relates to a recombined porcine vaccine comprising one such porcine adenovirus. The invention further relates to a serotype 3 or 5 porcine adenovirus vector that is replicative in vivo and is deleted in a non-essential region of the genome thereof. The invention also relates to a DNA fragment comprising all or part of the referenced SEQ ID NO.5 nucleotide sequence.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.